Protein kinase AEK1 as a T. brucei drug target and its potential in other trypanosomatids

Information

  • Research Project
  • 9453919
  • ApplicationId
    9453919
  • Core Project Number
    R21AI130685
  • Full Project Number
    1R21AI130685-01A1
  • Serial Number
    130685
  • FOA Number
    PA-16-161
  • Sub Project Id
  • Project Start Date
    5/8/2018 - 6 years ago
  • Project End Date
    4/30/2020 - 4 years ago
  • Program Officer Name
    O'NEIL, MICHAEL T
  • Budget Start Date
    5/8/2018 - 6 years ago
  • Budget End Date
    4/30/2019 - 5 years ago
  • Fiscal Year
    2018
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    5/7/2018 - 6 years ago

Protein kinase AEK1 as a T. brucei drug target and its potential in other trypanosomatids

ABSTRACT Trypanosomatid parasites cause some of the most challenging neglected diseases worldwide. The human- pathogenic triumvirate of Trypanosoma brucei spp., Trypanosome cruzi, and Leishmania spp. sickening hundreds of thousands of individuals, causing human African trypanosomiasis, Chagas' disease, and a range of visceral to cutaneous lesions, respectively. However, there are no approved vaccines and treatments are difficult due to side-effects, resistance, and regimens that are unsuitable for resource-limited settings. Therefore, discovery of new drugs is critical for therapy, control, and elimination of these diseases. We have recently shown that the protein kinase, AEK1, which is both highly conserved in these agents yet different from human protein kinases, is essential in the pathogenic bloodstream stage of T. brucei in vitro. We have also chemically validated it as important during infection. To discover T. brucei AEK1 inhibitors we will screen well- curated, focused kinase libraries against the purified enzyme, counterscreening against the closest human paralog, with subsequent testing of compounds on cultured bloodstream stage T. brucei. Such compounds will serve as a starting point for future work to develop drugs for treatment and eradication of human African trypanosomiasis. Surprisingly, few drug targets have been validated across pathogenic trypanosomatid species, despite their closely related proteomes. Therefore, we will test whether AEK1 could serve as a pan- trypanosomatid drug target by determining whether it is essential in the pathogenic stages of Leishmania donovani, and through collaboration, T. cruzi. If so, we will quantify activity of the discovered inhibitors against the L. donovani and T. cruzi enzymes and against L. donovani amastigotes. The results will inform us as to whether AEK1 is a suitable drug target for multiple parasite species, which would leverage future medicinal chemistry aimed at enhancing selectivity, efficacy and bioavailability of compounds identified in this project.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R21
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
    155542
  • Indirect Cost Amount
    149320
  • Total Cost
    304862
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:304862\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SEATTLE BIOMEDICAL RESEARCH INSTITUTE
  • Organization Department
  • Organization DUNS
    070967955
  • Organization City
    SEATTLE
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    981095240
  • Organization District
    UNITED STATES